Ocular Adverse Events Associated with Biologics Approved for Psoriasis: An FDA Adverse Event Reporting Database Study

Abstract

Keywords

biologics psoriasis adverse effects ocular

Get full access to this article

View all access options for this article.

References

Kamata

Tada

. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. doi:10.3390/ijms21051690

ABBVIE INC. HUMIRA® (adalimumab) Container/Carton Labels. Accessed September 18, 2024. https://www.fda.gov/drugsatfda

Castillejo

Becerra

Ding

Kenol

Hendershot

Meara

. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmol. 2020;5(1):e000331. doi:10.1136/bmjophth-2019-000331

Nicolela Susanna

Pavesio

. A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect. 2020;10(1):11. doi:10.1186/s12348-020-00202-6

Wendling

Paccou

Berthelot

, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503-510. doi:10.1016/j.semarthrit.2011.05.005

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB